phoebe

普衡律师事务所近日迎来调查和合规律师严妍以合伙人身份加盟其上海办事处生命科学及医疗保健业务部及调查与白领辩护业务部。此前,严律师执业于霍金路伟律师事务所。

严律师拥有超过10年的执业经验,在美国和中国政府部门的调查中代表跨国和中国公司,领域涉及反贿赂、反腐败、举报人引起的调查、利益冲突及其他问题,尤其专注生命科学领域客户。她持续向客户提供在美国《反海外腐败法》下美国司法部、美国证券交易委员会和其他监管机构发起的反贿赂合规和调查方面的咨询意见。

普衡生命科学及医疗保健业务全球主席Gary Giampetruzzi 表示:“严律师的加盟,和我们新建立的跨地区生命科学咨询业务和FDA监管业务部,反映了我们对客户不断变化的法律需求的持续回应,同时更拓展了我们向中国和亚太地区的客户所提供的丰富且有竞争力的服务领域。”

Paul Hastings continues to strengthen Life Sciences with partner hire from Hogan Lovells

Paul Hastings has hired investigations and compliance lawyer Phoebe Yan as a partner in Shanghai. Prior to joining Paul Hastings, Yan practiced at Hogan Lovells.

Yan has over 10 years experience representing multinational clients and Chinese companies in investigations by U.S. and Chinese government agencies, involving anti-bribery, anti-corruption, whistleblower claims, conflict of interests, and other issues, with particular emphasis on life sciences clients. She regularly advises clients on anti-bribery compliance and investigations under the U.S. Foreign Corrupt Practices Act, before the U.S. Department of Justice, U.S. Securities Exchange Commission, and other regulatory authorities.

“Along with the launching of our specialized, cross-office Life Sciences Consulting Group and our FDA practice, the addition of Phoebe reflects our continuous commitment to serve our clients’ evolving legal needs, and further augments our diverse, competitive offerings to clients in China and across Asia-Pacific,” said Gary Giampetruzzi, the Global Chair of Paul Hastings’ Life Sciences and Healthcare Practice.

 

To contact the editorial team, please email ALBEditor@thomsonreuters.com

Related Articles

华润饮料拟赴港上市(ZH/EN)

by Charlie Wu 吴卓言 |

华润饮料(控股)有限公司(华润饮料)已于4月22日向香港联合交易所递交上市申请。自2022年以来,华润饮料几度被传筹备推动华润饮料赴港上市,据彭博报道,该项目募资规模或达 10 亿美元。

通商、竞天公诚、君合等领衔助力第四范式、十月稻田香港上市(ZH/EN)

近日,香港资本市场迎来多宗重要上市项目,其中AI公司第四范式于国庆假期前登陆港交所,募资约1.07亿美元;食品品牌十月稻田则在假期后完成上市,募资约1.05亿美元。

七家律所参与香港首宗De-SPAC并购交易(ZH/EN)

by Mari Iwata |

近日,中国钢铁电商平台找钢产业互联集团(“找钢网”)与特殊目的收购公司(SPAC)Aquila Acquisition Corporation进行业务合并,成为自2022年1月1日香港引入SPAC上市机制以来香港首个SPAC并购交易,Aquila也是首家在香港上市的SPAC。